← Ishga qaytish
Ushbu ish iqtibos qilgan ishlar
298 ta ish
Ish: Pyroptosis-inducing nanomedicines: A dual-mode therapeutic framework for apoptosis-resistant lung cancer
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P. Dunn, Allen T. Bruce, Hiroaki Ikeda +2
Sharh maqola20022 iqtibosABIPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui +24
Maqola20152 iqtibosABIAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo +17
Maqola20182 iqtibosABIThe immune contexture in cancer prognosis and treatment
Wolf H. Fridman, Laurence Zitvogel, Catherine Sautès‐Fridman +1
Sharh maqola20172 iqtibosABIMitochondria as multifaceted regulators of cell death
Florian J. Bock, Stephen W. G. Tait
Sharh maqola20192 iqtibosABINivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro +23
Maqola20192 iqtibosABIPyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death
Jianjin Shi, Wenqing Gao, Feng Shao
Sharh maqola20162 iqtibosABICancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth
Sharh maqola20182 iqtibosABIPembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
Mao Lin, Haihua Luo, Shuzhen Liang +4
Maqola20202 iqtibosABIPolymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy
Nataša Avramović, Boris Mandić, Ana Savić-Radojević +1
Sharh maqola20202 iqtibosABITumor microenvironment complexity and therapeutic implications at a glance
Roghayyeh Baghban, Leila Roshangar, Rana Jahanban‐Esfahlan +6
Sharh maqola20202 iqtibosABI